Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer’s Disease - 21/11/24
, N. Andreasen 2, N. Prins 3
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Background |
KHK6640 is a novel humanized anti-amyloid beta oligomer-specific antibody. Both KHK6640 and the mouse parent antibody E64 have demonstrated high potency and efficacy for cognitive improvement in several rodent Alzheimer’s disease models, including an anti-amyloid beta injection mouse model and in age-matched double transgenic littermates. The favorable safety and pharmacokinetic profiles of KHK6640 reported in preclinical studies warrant clinical trials in Alzheimer’s disease patients.
Objectives |
We evaluated the safety, pharmacokinetics, and efficacy of intravenous and subcutaneous oligomer-specific antibody KHK6640 in treating patients with prodromal Alzheimer’s disease or mild to moderate Alzheimer’s disease. DESIGN: Phase I/2a, multicenter, randomized, double-blind, placebo-controlled trial.
Setting |
Nine sites in Europe participated in this clinical trial.
Participants |
97 patients with prodromal Alzheimer’s disease or mild to moderate Alzheimer’s disease.
Intervention |
Single and multiple ascending intravenous and subcutaneous doses of KHK6640 in doses ranging from 0.1 mg/kg to 20 mg/kg or placebo was administered to patients monthly for six months.
Measurements |
Primary outcomes were safety including amyloid-related imaging abnormalities for edema and hemorrhage, assessed with magnetic resonance imaging. Plasma and cerebrospinal fluid samples were analyzed to investigate pharmacokinetics and KHK6640 effects on biomarkers. Cognition, brain glucose metabolism and amyloid load were exploratory outcomes.
Results |
No amyloid-related imaging abnormalities for edema were observed. Amyloid-related imaging abnormalities for hemorrhage were comparable to that of placebo and population background. KHK6640 exposure was approximately dose-equivalent, with a serum terminal elimination half-life of approximately 19 days. KHK6640 pharmacokinetics in serum and cerebrospinal fluid, including cerebrospinal fluid oligomers trapped by the antibody were dose related. Positive trends seen in the positron emission tomography brain glucose metabolism and amyloid load, cerebrospinal tau but cognition assessments were inconclusive, due to low numbers.
Conclusions |
KHK6640 was well-tolerated across all doses, without any amyloid-related imaging abnormalities for edema, and amyloid-related imaging abnormalities for hemorrhage was as population background. The demonstrated dose-response of specific target biomarkers provides dosing guidance on dose and administration method selection for further clinical development.
Il testo completo di questo articolo è disponibile in PDF.Key words : Alzheimer’s disease, Amyloid-β, Oligomer, Immunotherapy, KHK6640
Mappa
| Disclosures: MC received consulting fees from Kyowa, CogRx, AlgRx, Acadia, Novartis, Jocasta and Schering. NDP consulting fees from Aribio, and Amylyx. He was a site PI on this KHK6640 trial sand co-PI of Fuji Film Toyama Chemical trial and received speaker fees from Biogen. NDP served on the DSMB of Abbvie’s M15-566 trial. NA He was a site PI on this KH6640 trial, and received consulting fees from Janssen, Lily, Eisai and Novaris. |
Vol 11 - N° 1
P. 65-70 - Gennaio 2024 Ritorno al numero
Articolo precedente
- Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force
- Maria Soto, P. Rosenberg, C. Ballard, B. Vellas, D. Miller, S. Gauthier, M.C. Carrillo, C. Lyketsos, Z. Ismail, Susan Abushakra, Mohammad Afshar, Sam Agus, Paul Aiden, John Alam, Alicia Algeciras-Schimnich, Sandrine Andrieu, Amos Baruch, Randall Bateman, Richard Batrla, Monika Baudler, Joanne Bell, Tobias Bittner, Sasha Bozeat, Joel Braunstein, Dawn Brooks, Tricia Brooks, Szofia Bullain, Jan Burmeister, Maria Carrillo, Min Cho, Emily Collins, Gavin Cook, Chris Dague, Susan De Santi, Rachelle Doody, Billy Dunn, Michael Egan, Sven Eriksson, Rianne Esquivel, Tom Fagan, Phyllis Ferrell, Howard Fillit, Michela Gallagher, Anna-Kaija Grönblad, Avis Hains, Harald Hampel, Oskar Hansson, Nanco Hefting, Suzanne Hendrix, Carole Ho, Helen Hu, Daryl Jones, Gene Kinney, Paul Kinnon, Ricky Kurzman, Lars Lannfelt, John Lawson, Nathalie LeBastard, Valérie Legrand, Nicole Lewandowski, Carine Lim, Donna Masterman, Colin Masters, Ming Lu, Mark Mintun, José Luis Molinuevo, Cecilia Monteiro, Bradford Navia, Tomas Odergren, Gunilla Osswald, Lewis Penny, Michael Pontecorvo, Anton Porsteinsson, Christine Rabe, Rema Raman, Gesine Respondek, Larisa Reyderman, Sharon Rogers, Paul Rosenberg, Sharon Rosenzweig-Lipson, Mark Roskey, Rubel Carrie, Ziad Saad, Stephen Salloway, Rachel Schindler, Dennis Selkoe, Melanie Shulman, John Sims, Kaycee Sink, Lisa Sipe, Daniel Skovronsky, Elizabeth Somers, Johannes Streffer, Pedro Such, Joyce Suhy, Masoud Toloue, Jacques Touchon, Manu Vandijck, Michael Weiner, Anne White, David Wilson, Wagner Zago, Jin Zhou, International CTAD Task Force members, EU/US CTAD Task force
- Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment
- Jeffrey N. Motter, S.N. Rushia, M. Qian, C. Ndouli, A. Nwosu, J.R. Petrella, P.M. Doraiswamy, T.E. Goldberg, D.P. Devanand
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.